# CBER

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/cber-organization
Canonical HTML page: https://getbiobrief.com/entity/cber-organization

## Timeline

- **2026-02-24**: Formal Proposal — FDA formally proposes the new customized drug approval system for ultra-rare diseases.
- **2025-11-10**: BGTC Pilot Completion — The Bespoke Gene Therapy Consortium completes its first round of pilot manufacturing runs.
- **2024-05-15**: Draft Guidance Issued — FDA releases initial thoughts on 'n-of-1' therapy development and manufacturing.
- **2022-12-29**: PREVENT Act Passed — Congress directs FDA to establish a framework for platform technology designations.

## Recent coverage (2 stories)

### FDA Vaccine Chief Departs Amid Regulatory Turmoil and Political Pressure
2026-03-07 01:54:04 · Sentiment: Negative · Impact: 6/10 · Sources: 6

The head of the FDA’s vaccine division is stepping down for the second time, marking a significant leadership vacuum at a critical juncture for the agency. This departure follows a period of intense scrutiny and reported friction between the regulatory body and the Trump administration over vaccine authorization protocols.
Full story: https://getbiobrief.com/story/fda-vaccine-chief-resignation-trump-administration

### FDA Unveils 'Platform' Pathway to Accelerate Bespoke Rare Disease Therapies
2026-02-24 03:18:36 · Sentiment: Positive · Impact: 8/10 · Sources: 2

The FDA has proposed a landmark regulatory framework to streamline the approval of customized, 'n-of-1' therapies for ultra-rare diseases. By shifting focus from individual products to validated manufacturing platforms, the agency aims to drastically reduce the time and cost of bringing genetic treatments to patients with unique mutations.
Full story: https://getbiobrief.com/story/fda-proposes-customized-drug-approval-system

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.